Monaco Asset Management SAM Has $3.78 Million Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Monaco Asset Management SAM raised its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 384,664 shares of the company’s stock after buying an additional 14,539 shares during the period. Ginkgo Bioworks comprises 0.5% of Monaco Asset Management SAM’s portfolio, making the stock its 18th biggest position. Monaco Asset Management SAM owned about 0.67% of Ginkgo Bioworks worth $3,777,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. PDT Partners LLC bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $1,199,000. Erste Asset Management GmbH acquired a new position in Ginkgo Bioworks in the third quarter worth $4,075,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Ginkgo Bioworks during the third quarter worth $2,282,000. BNP Paribas Financial Markets acquired a new stake in shares of Ginkgo Bioworks in the third quarter valued at $1,287,000. Finally, Verition Fund Management LLC bought a new position in shares of Ginkgo Bioworks in the third quarter valued at about $792,000. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Stock Down 2.9 %

Shares of NYSE DNA opened at $6.46 on Friday. The company has a market cap of $374.61 million, a price-to-earnings ratio of -0.49 and a beta of 1.23. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.26 and a 12-month high of $48.00. The firm’s 50-day simple moving average is $11.15 and its 200 day simple moving average is $9.20.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.